<DOC>
	<DOCNO>NCT00783406</DOCNO>
	<brief_summary>This study look pharmacokinetics , safety , toleration efficacy PF-00610355 chronic obstructive pulmonary disease ( COPD ) population . The dos study intend explore anticipated clinical dose range .</brief_summary>
	<brief_title>Safety , Toleration Efficacy Single Inhaled Doses PF-00610355 Chronic Obstructive Pulmonary ( COPD ) Patients .</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Postbronchodilator FEV1/ FVC ratio &lt; 0.7 . Post bronchodilator FEV1 5080 % ( inclusive ) predict . Body Mass Index ( BMI ) less 35 kg/m2 ; total body weight great 40 kg . Current smoker , exsmokers abstain smoke least 6 month . Subjects 2 exacerbation require treatment oral steroid hospitalization treatment COPD previous year . History low respiratory tract infection significant disease instability month precede screen period screen randomization .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>COPD</keyword>
</DOC>